Geoffrey Gurtner, MD, FACS
Geoffrey Gurtner, MD, FACS, is a scientist and entrepreneur who has launched start-up companies in the aesthetic, wound healing and cardiovascular fields. He is Director of Breast & Aesthetic Surgery at Stanford University, Stanford, CA, and a Professor of Surgery at Stanford University Medical Center. He also is a member of Stanford Cancer Institute, and a Professor and Associate Chairman of Surgery at Stanford Hospital.
Dr. Gurtner’s lab is interested in the mechanism of new blood vessel growth following injury and how pathways of tissue regeneration and fibrosis interact in wound healing. He is studying the development of a novel topical drug to heal wounds, particularly in diabetic populations. His work has identified deferoxamine (DFO), an iron chelator approved by the US Food and Drug Administration that increases the level HIF-1a protein, correcting the defects in diabetic neovascularizaton. His lab developed a DFO-encapsulated transdermal patch to accelerate wound healing without tissue necrosis. The strategy enhances local blood vessel formation and other hypoxia-induced responses, which has the potential to significantly reduce both the formation and progression of wound healing complications in diabetic patients.
Dr. Gurtner earned his MD at the University of California, San Francisco. He completed residencies at New York University Medical Center and Massachusetts General Hospital, Boston, and a fellowship at M.D. Anderson Cancer Center, Houston, Texas.
He has published more than 100 peer-reviewed articles. He is a general partner at TauTona Group, a medical device company, and founder/director at NeoDyne Biosciences, a tissue repair device company.